Free Trial

Vanguard Group Inc. Sells 53,448 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Charles River Laboratories International logo with Medical background

Key Points

  • Vanguard Group Inc. reduced its holdings in Charles River Laboratories International, Inc. by 0.9%, owning approximately 6.1 million shares valued at nearly $919 million as of the end of the first quarter.
  • Several institutional investors have increased their stakes, with Rothschild Investment LLC boosting its position by 480% during the same period.
  • Charles River Laboratories reported $3.12 EPS for the quarter, outperforming analysts' expectations of $2.50 and generating revenue of $1.03 billion.
  • Want stock alerts on Charles River Laboratories International? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Vanguard Group Inc. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 0.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,105,478 shares of the medical research company's stock after selling 53,448 shares during the quarter. Vanguard Group Inc. owned approximately 12.43% of Charles River Laboratories International worth $918,997,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Teacher Retirement System of Texas bought a new stake in Charles River Laboratories International during the 1st quarter valued at approximately $1,231,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Charles River Laboratories International by 15.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company's stock valued at $952,000 after acquiring an additional 817 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Charles River Laboratories International by 13.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock valued at $6,698,000 after acquiring an additional 5,148 shares in the last quarter. GAMMA Investing LLC boosted its position in Charles River Laboratories International by 61.6% during the 1st quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company's stock valued at $210,000 after acquiring an additional 533 shares in the last quarter. Finally, Concurrent Investment Advisors LLC bought a new stake in Charles River Laboratories International during the 1st quarter valued at approximately $213,000. 98.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Wall Street Zen raised Charles River Laboratories International from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their price target for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. Evercore ISI boosted their price target on Charles River Laboratories International from $180.00 to $190.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Robert W. Baird boosted their price target on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday, May 8th. Finally, Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Charles River Laboratories International has an average rating of "Hold" and a consensus price target of $175.69.

Check Out Our Latest Stock Analysis on Charles River Laboratories International

Charles River Laboratories International Stock Up 0.6%

NYSE CRL traded up $0.86 during mid-day trading on Friday, reaching $156.66. The stock had a trading volume of 1,038,291 shares, compared to its average volume of 1,079,568. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $230.02. The stock has a market cap of $7.71 billion, a PE ratio of -117.79, a price-to-earnings-growth ratio of 4.97 and a beta of 1.48. The company has a fifty day moving average price of $156.87 and a 200 day moving average price of $148.95. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company's quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.80 EPS. On average, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 400 shares of the business's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $150.04, for a total transaction of $60,016.00. Following the completion of the sale, the executive vice president directly owned 24,916 shares in the company, valued at approximately $3,738,396.64. The trade was a 1.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company's stock.

About Charles River Laboratories International

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Recommended Stories

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Should You Invest $1,000 in Charles River Laboratories International Right Now?

Before you consider Charles River Laboratories International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.

While Charles River Laboratories International currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines